NasdaqCM - Delayed Quote USD

ChromaDex Corporation (CDXC)

3.7900 -0.1800 (-4.53%)
At close: April 18 at 4:00 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Frank Louis Jaksch Jr. Co-Founder & Chairman 292.27k -- 1968
Mr. Robert N. Fried CEO & Director 735.54k -- 1960
Ms. Brianna Gerber Chief Financial Officer 509.82k -- 1981
Dr. Andrew Shao Ph.D. Senior Vice President of Global Regulatory & Scientific Affairs -- -- --
Heather Van Blarcom Senior VP of Legal & Corporate Secretary -- -- --
Alex Worsham Vice President of Global Marketing & Communications -- -- --
Mr. David Kroes Senior Vice President of People Matters -- -- --
Ms. Chu Yan Managing Director of Asia Pacific -- -- --
Mr. Jason Campbell Senior Vice President of Business Development -- -- --
Kendall Knysch Head of Media Relations & Partnerships -- -- --

ChromaDex Corporation

10900 Wilshire Blvd
Suite 600
Los Angeles, CA 90024
United States
310 388 6706 https://www.chromadex.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
106

Description

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The company also commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient NIAGEN; NIAGEN as an active ingredient in its consumer products under the TRU NIAGEN name; and Immulina, a spirulina extract with predominant active compounds of Braun-type lipoproteins for supporting human immune function. In addition, it offers phytochemical reference standards, and other research and development services. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, ShopHQ, and other internet marketplaces, as well as specialty retailers and direct healthcare practitioners in the United States. ChromaDex Corporation was founded in 1999 and is headquartered in Los Angeles, California.

Corporate Governance

ChromaDex Corporation’s ISS Governance QualityScore as of April 1, 2024 is 5. The pillar scores are Audit: 8; Board: 6; Shareholder Rights: 2; Compensation: 6.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

Upcoming Events

May 08, 2024 - May 13, 2024
ChromaDex Corporation Earnings Call

Related Tickers